Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Company Description and Summary of Significant Accounting Policies [Abstract]
Transfers in into Level 3	$ 0	$ 0
Transfers out of Level 3	0	$ 0
Recurring Basis [Member]
Assets [Abstract]
Assets at fair value	126		$ 219
Recurring Basis [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	126		219
Recurring Basis [Member] \| Level 1 [Member]
Assets [Abstract]
Assets at fair value	126		219
Recurring Basis [Member] \| Level 1 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	126		219
Recurring Basis [Member] \| Level 2 [Member]
Assets [Abstract]
Assets at fair value	0		0
Recurring Basis [Member] \| Level 2 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	0		0
Recurring Basis [Member] \| Level 3 [Member]
Assets [Abstract]
Assets at fair value	0		0
Recurring Basis [Member] \| Level 3 [Member] \| Short- term investments [Member]
Assets [Abstract]
Assets at fair value	$ 0		$ 0